Pasatru shows no new HO lesions in FOP patients in OPTIMA extension
New data from the OPTIMA trial extension suggest that Pasatru, a medicine previously approved to treat fibrodysplasia ossificans progressiva (FOP), continued to show sustained benefit through 84 weeks by preventing new abnormal bone formation and reducing disease flare-ups in adults with FOP. The findings were presented at a major bone-health conference after an initial 56-week trial led to FDA approval.
What changed in the 84-week data
The OPTIMA trial extension followed adults with FOP receiving Pasatru for up to 84 weeks. Clinically, researchers reported ongoing reductions in new heterotopic ossification (HO) lesions and fewer flare-ups, compared with earlier results. This suggests that longer treatment may sustain disease control for some patients. Heterotopic ossification means unwanted bone growth outside the normal skeleton, which can limit movement and cause pain. Presentations emphasized the durability of Pasatru’s effects over an extended period.
Key facts about the findings
Pasatru is the branded name for garetosmab-grts. In the OPTIMA extension, adults with FOP showed continued suppression of new HO lesions and a persistent reduction in clinician-assessed flare-ups through 84 weeks. This aligns with the drug’s prior FDA-approved 56-week trial outcomes. The safety profile remained consistent with earlier results, supporting the potential for long-term disease control in this patient group.
Who is affected
The news concerns adults diagnosed with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition characterized by abnormal bone formation that can occur after injuries or spontaneously. Pasatru is used to slow the formation of new HO and reduce flare-ups in this population. FOP patients vary in symptoms, but HO growth can progressively restrict movement and function.
Practical next steps for patients and caregivers
Patients advised to discuss ongoing treatment plans with their clinician, especially if considering continued Pasatru therapy beyond the initial trial period. Families and caregivers should monitor for signs of new HO lesions or flare-ups and report any adverse effects to healthcare providers. Researchers may continue to study long-term effects to determine the best duration and dosing for various patient subgroups.
Limits and open questions
Details about the full safety profile over the 84-week period and how results vary among individuals were not fully summarized here. It is not yet clear how long benefits continue beyond 84 weeks for all patients or how Pasatru compares with other therapies in real-world use. Stakeholders may await peer-reviewed publication and guidance from health authorities on long-term management strategies.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- biospace.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.